Navigation Links
ADVENTRX Announces Signing of Term Sheet for Acquisition of Poloxamer-Based Therapeutics
Date:1/7/2011

re may benefit patients with sickle cell disease in acute crisis, which is associated with microvascular occlusion. A phase 3 study in this indication previously was initiated by a prior sponsor of the TPC, but was discontinued primarily due to inadequate capital being available to continue.

About ADVENTRX Pharmaceuticals

ADVENTRX Pharmaceuticals is a specialty pharmaceutical company whose product candidates are being developed to improve the performance of existing anti-cancer drugs by addressing limitations associated principally with their safety and use.  More information can be found on the Company's web site at www.adventrx.com.

Forward Looking Statements

ADVENTRX cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements that are based on ADVENTRX's current expectations and assumptions. Such forward-looking statements include, but are not limited to, statements regarding the terms and conditions of an acquisition transaction with the target company, retaining services of members of the target company's management team following the transaction, use of the TPC to treat patients with sickle cell disease in acute crisis, initiation of a phase 3 clinical trial of the TPC for the treatment of sickle cell crisis, the amount and timing of out-of-pocket cost to ADVENTRX to submit an NDA covering the TPC, and orphan drug designation for the TPC for the treatment of sickle cell crisis.  Actual events or results may differ materially from those expressed or implied by the forward-looking statements in this press release due to a number of risks and uncertainties, including, without limitation: the risk that ADVENTRX does not enter into definitive agreements or consummate a transaction with the target company on a timely basis, or at all; the potential for the definitive agreements, if any, to reflect
'/>"/>

SOURCE ADVENTRX Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
2. ADVENTRX Announces Completion of Patient Enrollment in ANX-530 Marketing-Enabling Clinical Study
3. ADVENTRX Meets Primary Endpoint in ANX-530 Marketing-Enabling Clinical Study
4. ADVENTRX Announces Completion of Patient Enrollment in Phase 2 Clinical Trial of CoFactor(R) for the Treatment of Advanced Breast Cancer
5. ADVENTRX to Present ANX-201 Preclinical Data at Keystone Symposia HIV Pathogenesis Conference
6. ADVENTRX to Present CoFactor Phase 2 Breast Cancer Data at the 2008 Annual Meeting of the American Society of Clinical Oncology (ASCO)
7. ADVENTRX Announces ANX-530 Safety Data From Registrational Bioequivalence Clinical Study
8. ADVENTRX Presents CoFactor Data at the 2008 Annual Meeting of the American Society of Clinical Oncology (ASCO)
9. ADVENTRX Announces CoFactor(R) Phase 2b Clinical Trial Overall Survival Results
10. ADVENTRX Announces Preliminary Response Rate Data From Discontinued Phase 3 Trial of CoFactor(R)
11. ADVENTRX Completes Patient Enrollment in ANX-514 Bioequivalence Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... N.Y. , Aug. 22, 2014  Mark ... tomography (CT) imaging facility, is using the online ... and even 5D imaging to researchers and would-be ... launched, asks "What would YOU do if you ... possibility to researchers and explorers everywhere, from elementary ...
(Date:8/22/2014)... 2014  WaferGen Bio-systems, Inc. (NASDAQ: WGBS) today announced ... of common stock and warrants at a price of ... prior to deducting underwriting discounts and commissions and offering ... are immediately separable and will be issued separately.  The ... on The NASDAQ Stock Market under the ticker symbol ...
(Date:8/21/2014)... Aug. 21, 2014  eRelevance Corporation ( www.erelevancecorp.com ... today that it has completed integration with Nextech, ... Plastic Surgery and Dermatology practices. "Integration ... to healthcare practices using Nextech," stated Bob ... "Using information from the EMR we are able ...
Breaking Medicine Technology:Cornell's X-ray Imaging Lab Director Uses Kickstarter Campaign to "Democratize" Advanced 3D Imaging 2WaferGen Bio-Systems Announces Pricing of $20 Million Underwritten Offering and Uplisting to NASDAQ 2WaferGen Bio-Systems Announces Pricing of $20 Million Underwritten Offering and Uplisting to NASDAQ 3WaferGen Bio-Systems Announces Pricing of $20 Million Underwritten Offering and Uplisting to NASDAQ 4eRelevance Corporation Integrates with Nextech Electronic Medical Records 2
... 21, 2012 Anthera Pharmaceuticals, Inc. (NASDAQ: ANTH ... quarter ended December 31, 2011. Financial Results: ... ended December 31, 2011 were $28.4 million, as compared to ... 12 months ended December 31, 2011, total operating expenses were ...
... Link Platform:  BNVI.PK), a pharmaceutical company focused on the ... women,s health and cancer, today announced its decision to ... the Company has decided to delay the announcement of ... 2011, previously planned for today, to a later date.  ...
Cached Medicine Technology:Anthera Pharmaceuticals Reports 2011 Fourth Quarter Financial Results and Provides Clinical Progress Update 2Anthera Pharmaceuticals Reports 2011 Fourth Quarter Financial Results and Provides Clinical Progress Update 3Anthera Pharmaceuticals Reports 2011 Fourth Quarter Financial Results and Provides Clinical Progress Update 4Anthera Pharmaceuticals Reports 2011 Fourth Quarter Financial Results and Provides Clinical Progress Update 5Anthera Pharmaceuticals Reports 2011 Fourth Quarter Financial Results and Provides Clinical Progress Update 6Bionovo Announces Decision to Explore Strategic Options and to Delay Announcement of Financial Results for 2011 2Bionovo Announces Decision to Explore Strategic Options and to Delay Announcement of Financial Results for 2011 3
(Date:8/22/2014)... Today, Zane Benefits, the #1 Online Health ... Plans. , According to Zane Benefits, employers are adopting ... the cost of healthcare without reducing coverage for employees. ... can be confusing. , The new guide contains a ... types of ABHPs. It also explains the similarities, ...
(Date:8/22/2014)... 22, 2014 MyWriters.com , an ... by marketing experts for marketers to help them drive ... the attention of Shane Michaels, prompting an investigative review. ... in any way knows that content is king when ... reports Michaels. “But even though content is extremely important, ...
(Date:8/22/2014)... Buying a policy for different life insurance ... about available coverage types by insurers in the U.S. The ... pricing to the public using its sortable tool at ... free and is expected to promote the discounts and special ... the U.S. The system is designed to help an adult ...
(Date:8/22/2014)... Worth, FL (PRWEB) August 22, 2014 Millennium ... of marijuana, resulting in a high level of drug use ... all ages fight against drug addiction and work to minimize ... highest levels of alcohol and drug addiction in history. According ... 2012, an estimated 23.9 million Americans aged 12 or older—or ...
(Date:8/22/2014)... By Amy Norton ... (HealthDay News) -- A growing number of Americans on ... a new study. Researchers found that between 2007 ... Security Disability Insurance benefits were prescribed narcotic painkillers each ... from 21 percent in 2007 to 23 percent in ...
Breaking Medicine News(10 mins):Health News:My Writers: Review Exposes Online Source for Quality Marketing Content 2Health News:Principal Life Insurance Policies Now Quoted for Adults at Insurance Website Online 2Health News:Millennium Treatment Group Sees Increase in Marijuana Use Among Youth 2Health News:Many U.S. Workers on Disability Use Narcotic Painkillers, Study Finds 2Health News:Many U.S. Workers on Disability Use Narcotic Painkillers, Study Finds 3Health News:Many U.S. Workers on Disability Use Narcotic Painkillers, Study Finds 4
... the Escorts hospital here will soon get a Rs.300 million ... ,"We will invest Rs.30 crore (Rs.300 million) in Escorts within ... Monday. ,"Due to Dr. Naresh Trehan's focus on ... focus for the last 20 months. With Naresh no more ...
... anxious about their fertility can feel a bit relaxed now. ... fertility screening test, called Fertell. The test has his ... is the first at-home device to measure the concentration of ... hormone considered a marker of egg quality. ,The ...
... pregnant women can cause disorders in their children, says ... behavioural problems which are part of fetal alcohol spectrum ... lives of the individual and those around them. A ... conditions are completely preventable by not drinking any alcohol ...
... Abuse and Mental Health Services Administration (SAMHSA) today ... million over three years to the state ... Intervention Project. The first year award is $400,000. ... to early intervention and treatment services for youth ...
... revealed that stress boosts the production of a brain ... on mice has now shown that blocking a different ... reported online in the Proceedings of the National Academy ... Medicine in St. Louis, is among the first studies ...
... The International Myeloma Foundation (IMF)-supporting research and providing ... families, researchers and physicians-today said that data from ... clinical trial shows the combination of DOXIL(R) with ... ,The follow-up study also showed no ...
Cached Medicine News:Health News:Fortis to Inject Rs.300 Mn into Escorts Hospital 2Health News:Fertility Test at Home Possible With a New Kit 2Health News:Pregnancy and Alcohol - a Dangerous Cocktail Warns BMA Scotland 2Health News:Iowa to Receive Grant Funding for Youth Suicide Prevention, Early Intervention 2Health News:Stress Protein Inactivation Cuts Alzheimer's Peptide in Mice 2Health News:Velcade(R) Plus Doxil(R) Improves Previously Treated Multiple Myeloma Patients 2
HME w/bacterial viral filter w/CO2...
Indications For Usage: ,Infant (recommended tidal volume 20-70ml), single patient use on anesthetized patients and respiratory care patients who require a breathing circuit. The product is intended ...
... The Portex® Thermovent® T helps provide protection to ... is small and extremely lightweight making it ideal ... With a high rate of heat and moisture ... retention., ,All HMEs and filters have ISO ...
... The Portex® Thermovent® T helps provide protection to ... is small and extremely lightweight making it ideal ... With a high rate of heat and moisture ... retention., ,All HMEs and filters have ISO ...
Medicine Products: